Searching where to buy tesamorelin brings up very different products.
Some pages refer to the FDA-approved prescription medicine. Others sell peptide material for laboratory or analytical work.
That distinction matters.
Tesamorelin is a synthetic growth hormone-releasing factor analog. It contains the 44-amino-acid sequence of human GRF plus an N-terminal hexenoyl modification. DailyMed lists its free-base-equivalent molecular weight as approximately 5,135.9 Da. PubChem reports the molecular formula as C221H366N72O67S.
Therefore, buyers should first define what they are actually purchasing.
There are two very different purchasing routes.
For medical use in the United States, tesamorelin is available as the prescription product EGRIFTA. FDA’s Purple Book lists Egrifta, Egrifta SV, and Egrifta WR under BLA 022505.
DailyMed lists EGRIFTA WR as an Rx-only product. Its current formulation contains 11.6 mg of tesamorelin per vial.
Research suppliers, meanwhile, offer peptide material under different specifications. Current search-visible examples advertise lyophilized material, batch COAs, HPLC purity data, and mass-spectrometry identity confirmation. Those products should not be represented as substitutes for EGRIFTA.
| Product Type | Typical Documentation | Primary Channel | Key Check |
|---|---|---|---|
| FDA-approved tesamorelin | FDA-approved labeling | Licensed pharmacy | Valid prescription |
| Research peptide material | Supplier COA, HPLC, MS | Research supplier | Lot-specific test data |
| Analytical reference material | Identity and analytical records | Scientific supplier | Traceability |
The official product and commercial research materials follow different regulatory and quality pathways. Buyers should not judge them by vial size alone.
A good supplier page should provide more than a purity percentage.
Start with the batch number.
Next, check whether the COA matches that batch. Then review the analytical methods.
For peptide materials, HPLC can help assess chromatographic purity. Mass spectrometry can provide identity information.
FDA material on peptide quality control also describes LC-MS and LC-MS/MS as useful tools for analyzing peptide mixtures and peptide-related impurities.
Therefore, a stronger documentation package may contain:
A simple “99% purity” badge provides much less information.
Consider a biotechnology company sourcing tesamorelin for an analytical project.
The team needs 20 mg for method development.
Supplier A states “99% purity.” However, it provides no chromatogram.
Supplier B provides a lot-specific COA. The COA includes an HPLC trace and MS result.
Supplier C provides similar data, but its COA lacks the lot number shown on the vial.
In this example, Supplier B offers the clearest traceability.
Price still matters. However, documentation should come first.
The buyer can then request the following:
“Please provide the lot-specific COA, HPLC chromatogram, MS identity data, available quantity, storage conditions, and batch traceability before quotation.”
That single request quickly separates detailed suppliers from basic resellers.
Tesamorelin differs from many peptides because controlled human studies support an FDA-approved indication.
Two randomized, placebo-controlled studies evaluated the older EGRIFTA formulation in adults with HIV-associated lipodystrophy.
In Study 1, 273 participants received tesamorelin and 137 received placebo. Mean VAT changed by -18% and +2%, respectively.
In Study 2, 270 participants received tesamorelin and 126 received placebo. Mean VAT changed by -14% and -2%.
However, these results relate to the approved clinical setting.
The label specifically states that EGRIFTA WR is not indicated for weight-loss management.
That distinction should remain clear on any scientifically responsible website.
There is no universal “best” source.
Instead, the best channel depends on purpose.
For prescription treatment in the United States, use the legitimate healthcare and licensed-pharmacy route.
For laboratory procurement, compare suppliers through documentation, analytical data, traceability, and specification fit.
Therefore, avoid choosing solely through:
“lowest price,”
“99% purity,” or
“fast shipping.”
Those claims do not establish identity by themselves.
Before completing a research purchase, confirm:
Identity → Purity → Quantity → Batch → COA → Test method → Storage → Traceability.
This approach creates a much stronger purchasing process.
For prescribed EGRIFTA in the U.S., use a licensed pharmacy and valid prescription. Research material follows a different procurement channel.
Tesamorelin is FDA licensed under Egrifta products for reduction of excess abdominal fat in adults with HIV and lipodystrophy. It is not approved as a general weight-loss medicine.
For research procurement, a lot-specific COA greatly improves traceability. Ideally, it should connect the vial, batch number, test results, and analytical records.
